• Improving Patient 
    Outcomes in
    Solid Tumor
    Cancer Treatment

    BIO300
    A New Class of Cancer Drug

  •  

    COVID-19

     

    BIO300
    Preventing long term lung damage caused by inflammation

  • Keeping America Safe

    BIO300
    Protecting Civilians, First Responders and Our Military
    from Nuclear Accidents and Terrorism

Humanetics News

10.03.2024

Humanetics Corporation Presents at the 2024 Department of Defense Scientific Meeting
Read More

10.01.2024

Humanetics to Participate in the BIO Investor Forum in San Franciscio
Read More

08.13.2024

Uniformed Services University Awards Grant to Support Continued Collaboration with Humanetics to Develop Radiation Countermeasure
Read More

05.31.2024

Humanetics to Present at the BIO International Convention in San Diego
Read More

02.13.2024

Humanetics Presents at Oppenheimer 34th Annual Healthcare Life Science Conference
See Presentation

02.06.2024

Humanetics to Present at Investor and Partnering Conferences
Read More

12.12.2023

Major General (Ret.) Barbara R. Holcomb Joins Board at Humanetics
Read More

11.14.2023

Humanetics Appoints Dr. Colin Chinn as Chief Medical Officer
Read More

09.19.2023

Humanetics Publishes Positive Clinical Trial Results of BIO 300 in Patients with NSCLC
Read More

10.24.2023

Humanetics Receives Funding to Study BIO 300 as Treatment for Idiopathic Pulmonary Fibrosis
Read More

09.06.2023

Humanetics Awarded Contract from Dept. of Defense to Develop First FDA Approved Drug to Prevent Radiation Injury
Read More

05.24.2023

BIO 300 Enhances Efficacy of Radiotherapy Against Lung Tumors in a Nonclinical Model
Read More

08.22.2023

BIO 300 Featured at Military Health System Research Symposium
Read More

02.15.2023

Humanetics  Announces Positive Results from Independent Data Monitoring Committee Review of Phase 2 Trial in COVID-19 Patients
Read More

02.07.2023

BIO 300 Demonstrates Protection Against Radiation-Induced Lung Injury
Read More